Suppr超能文献

NO/cGMP 抑制剂在过敏性休克大鼠模型中的作用。

Effects of NO/cGMP inhibitors in a rat model of anaphylactoid shock.

机构信息

Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.

Departamento de Biociências, Instituto de Saúde e Sociedade, Campus Baixada Santista, Universidade Federal de São Paulo, Santos, SP, Brasil.

出版信息

Braz J Med Biol Res. 2020 Mar 2;53(3):e8853. doi: 10.1590/1414-431X20198853. eCollection 2020.

Abstract

Anaphylactic shock can be defined as an acute syndrome, and it is the most severe clinical manifestation of allergic diseases. Anaphylactoid reactions are similar to anaphylactic events but differ in the pathophysiological mechanism. Nitric oxide (NO) inhibitors during anaphylaxis suggest that NO might decrease the signs and symptoms of anaphylaxis but exacerbate associated vasodilation. Therefore, blocking the effects of NO on vascular smooth muscle by inhibiting the guanylate cyclase (GC) would be a reasonable strategy. This study aimed to investigate the effects of NO/cGMP pathway inhibitors methylene blue (MB), Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), and indigo carmine (IC) in shock induced by compound 48/80 (C48/80) in rats. The effect was assessed by invasive blood pressure measurement. Shock was initiated by C48/80 intravenous bolus injection 5 min before (prophylactic) or after (treatment) the administration of the inhibitors MB (3 mg/kg), L-NAME (1 mg/kg), and IC (3 mg/kg). Of the groups that received drugs as prophylaxis for shock, only the IC group did not present the final systolic blood pressure (SBP) better than the C48/80 group. Regarding shock treatment with the drugs tested, all groups had the final SBP similar to the C48/80group. Altogether, our results suggested that inhibition of GC and NO synthase in NO production pathway was not sufficient to revert hypotension or significantly improve survival.

摘要

过敏性休克可定义为一种急性综合征,是过敏疾病最严重的临床表现。过敏样反应类似于过敏性事件,但在病理生理学机制上有所不同。在过敏反应期间使用一氧化氮 (NO) 抑制剂表明,NO 可能会减轻过敏反应的体征和症状,但会加重相关的血管扩张。因此,通过抑制鸟苷酸环化酶 (GC) 来阻止 NO 对血管平滑肌的作用可能是一种合理的策略。本研究旨在探讨 NO/cGMP 通路抑制剂亚甲蓝 (MB)、Nω-硝基-L-精氨酸甲酯盐酸盐 (L-NAME) 和靛红 (IC) 对化合物 48/80 (C48/80) 诱导的大鼠休克的影响。通过有创血压测量评估效果。在抑制剂 MB(3mg/kg)、L-NAME(1mg/kg)和 IC(3mg/kg)给药前 5 分钟(预防)或给药后(治疗)静脉推注 C48/80 引发休克。在接受药物预防休克的组中,只有 IC 组的终末收缩压 (SBP) 不比 C48/80 组好。关于用测试药物治疗休克,所有组的终末 SBP 与 C48/80 组相似。总的来说,我们的结果表明,抑制 GC 和 NO 合酶在 NO 产生途径中不足以逆转低血压或显著提高生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/544c/7057939/8c42c7112fb0/1414-431X-bjmbr-53-3-e8853-gf001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验